CTI BioPharma (NASDAQ:CTIC) Given New $8.00 Price Target at

CTI BioPharma (NASDAQ:CTIC – Get Rating) had its price objective lowered by TD Cowen from $10.00 to $8.00 in a research note released on Monday, Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on CTIC. StockNews.com raised CTI BioPharma from […]

Related Keywords

Adamr Craig , Jamesk Fong , , Vanguard Group Inc , Needham Company , Stonepine Capital Management , Biopharma Corp , Sofinnova Investments Inc , Blackrock Inc , Get Rating , Moderate Buy , Pharma Price , Street Corp , Capital Management , Sofinnova Investments , Pharma Daily , Cti Biopharma , Nasdaq Ctic , Arctic , Medical , Lower Price Target , Td Cowen ,